ProBioGen, a Contract Development & Manufacturing Organization (CDMO), has partnered with DIOSynVax Ltd to manufacture DIOS-HFVac3, a trivalent hemorrhagic fever (HF) vaccine that was developed in collaboration with the Molecular Virology, Institute of Medical Microbiology and Hygiene, University of Regensburg.
ProBioGen and ImmunOs Therapeutics have extended their partnership for further large-scale manufacturing of clinical material for IOS-1002, ImmunOs' lead program for the treatment of cancer. ProBioGen previously developed the cell line and the manufacturing process and provided the initial clinical material for ImmunOs' biologic.
ProBioGen and ImmunOs Therapeutics announce the extension of their partnership for further large-scale manufacturing of clinical material for IOS-1002, ImmunOs' lead program for the treatment of cancer. ProBioGen previously developed the cell line and the manufacturing process and provided the initial clinical material for ImmunOs' innovative biologic.
ProBioGen is announcing another important clinical milestone for its proprietary viral vector and vaccine production cell line AGE1.CRpIX®. Our valued customer Nouscom recently proclaimed that their sub-licensee, has initiated phase 1 clinical trials for VAC85135, a viral vector-based cancer vaccine for an oncologic indication. The MVA-based component of the vaccine was produced using ProBioGen's AGE1.CR.pIX.
ProBioGen entered a new non-exclusive collaboration with Boehringer Ingelheim on ProBioGen's DirectedLuck transposase technology. Financial terms of the agreement were not disclosed.
Following the success of the Gibco Freedom CHO-S Cell Line Development Kit, ProBioGen and Thermo Fisher Scientific have teamed up again to develop an even better platform: the Gibco Freedom ExpiCHO-S Cell Line Development Kit.
Granite Bio, a Swiss biotech company built through Versant Venture's discovery engine Ridgeline Discovery, and ProBioGen, a contract development and manufacturing organization (CDMO), have closed a Master Services Agreement to support the development of Granite Bio's mAb pipeline.
The new project is a continuation of successfully completed cell line development work that utilized ProBioGen's proprietary technologies. The new program includes upstream and downstream process development and large-scale GMP production. In addition, ProBioGen's cell and tissue services department will develop several cell-based bioassays to thoroughly characterize the molecule. Under the previous license agreement, ProBioGen is eligible to receive milestone payments. Further financial details were not disclosed.
ProBioGen has announced a multi-product commercial licence agreement with AstraZeneca to use the GlymaxX technology, ProBioGen said in a statement.
ProBioGen announced that Innovent Biologics, Inc. (1801.HK) has signed a multi-product license for ProBioGen's GlymaxX technology.